KRAS and pancreatic neoplasm: In a study with the MEK inhibitor cobimetinib plus gemcitabine in 13 patients with pancreatic cancer, all six patients with KRAS G12R mutated cancers achieved disease control, with one partial response and five with stable disease resulting in a median PFS of 6 months.